BioCryst Pharmaceuticals Inc logo

BCRX - BioCryst Pharmaceuticals Inc Share Price

$3.04 0.1  3.8%

Last Trade - 4:45pm

Small Cap
Market Cap £346.0m
Enterprise Value £354.5m
Revenue £9.07m
Position in Universe 3113th / 6416
Unlock BCRX Revenue
Relative Strength (%)
Volume Change (%)
10d / 3m
Price vs... (%)
52w High
50d MA
200d MA
Margin of Safety
Qualifying GuruScreens
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History


BCRX Revenue Unlock BCRX Revenue

Net Income

BCRX Net Income Unlock BCRX Revenue

Normalised EPS

BCRX Normalised EPS Unlock BCRX Revenue

PE Ratio Range

BCRX PE Ratio Range Unlock BCRX Revenue

Dividend Yield Range

BCRX Dividend Yield Range Unlock BCRX Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2020
31st Dec 2021
Est. Long Term Growth Rate: Net Profit
Net Profit
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
BCRX EPS Forecasts Unlock BCRX Revenue
Profile Summary

BioCryst Pharmaceuticals, Inc. is a biotechnology company. The Company designs, optimizes and develops small molecule drugs that block enzymes involved in the pathogenesis of diseases. The Company focuses on the treatment of rare diseases. It uses X-ray crystallography, computer modeling of molecular structures and chemistry techniques to focus on the three-dimensional molecular structure and active site characteristics of the enzymes that control cellular biology. The Company's drug candidates include RAPIVAB, RAPIACTA, ALPIVAB, PERAMIFLU, Avoralstat, BCX7353, other second generation hereditary angioedema (HAE) compounds, Galidesivir and Forodesine. Its product RAPIVAB contains peramivir. ALPIVAB is an intravenous neuraminidase inhibitor. Galidesivir is a broad-spectrum antiviral (BSAV) research program developed for the treatment of hemorrhagic fever viruses. Forodesine is a Purine Nucleoside Phosphorylase (PNP) inhibitor in development by Mundipharma as a treatment for cancer.

Last Annual December 31st, 2018
Last Interim September 30th, 2019
Incorporated November 15, 1991
Public Since March 4, 1994
No. of Shareholders: 170
No. of Employees: 100
Sector Healthcare
Industry Biotechnology & Medical Research
Index Nasdaq Composite ,
Exchange NASDAQ Global Select Market
Shares in Issue 154,059,115
Free Float (0.0%)
Eligible for
BCRX Share Price Performance
Share Price
Bid - Ask
Low - High
Day's Change
Avg Volume
Open - Close
Range (12m)
Latest News for BCRX
Upcoming Events for BCRX
Monday 2nd March, 2020 Estimate
Q4 2019 BioCryst Pharmaceuticals Inc Earnings Release
Wednesday 6th May, 2020 Estimate
Q1 2020 BioCryst Pharmaceuticals Inc Earnings Release
Thursday 28th May, 2020 Estimate
BioCryst Pharmaceuticals Inc Annual Shareholders Meeting
Similar to BCRX
© Stockopedia 2020, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.